Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3<i>R</i>)-7-Hydroxy-<i>N</i>-[(1<i>S</i>)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic)
作者:Pauline W. Ondachi、Chad M. Kormos、Scott P. Runyon、James B. Thomas、S. Wayne Mascarella、Ann M. Decker、Hernán A. Navarro、Timothy R. Fennell、Rodney W. Snyder、F. Ivy Carroll
DOI:10.1021/acs.jmedchem.8b00673
日期:2018.9.13
dine-1-yl)methyl]propyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (12) (4-Me-PDTic). Compound 12 had a Ke = 0.37 nM in a [35S]GTPγS binding assay and was 645- and >8100-fold selective for the κ relative to the μ and δ opioid receptors, respectively. Calculated log BB and CNS (central nervous system) multiparameter optimization (MPO) and low molecular weight values all predict that 12 will penetrate
过去的研究表明,很难发现和开发有效且选择性的κ阿片受体拮抗剂,尤其是具有临床开发潜力的化合物。在这项研究中,我们对最近发现的新型四氢异喹啉κ阿片受体拮抗剂进行了结构-活性关系(SAR)研究,该拮抗剂导致(3 R)-7-羟基-N -(1 S)-2-甲基-1-[(-4-甲基哌啶-1-基)甲基]丙基} -1,2,3,4-四氢异喹啉-3-羧酰胺(12)(4-Me-PDTic)。化合物12有ķ ë = 0.37 nM的在[ 35S]GTPγS结合试验,相对于μ和δ阿片受体,对κ的选择性是645倍和> 8100倍。计算出的log BB和CNS(中枢神经系统)多参数优化(MPO)和低分子量值都预示着12个会穿透大脑,并且在大鼠体内的药代动力学研究表明,确实有12个会穿透大脑。